Articles tagged with Cancer Patients
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A study of UK patients diagnosed with colorectal cancer between 2006 and 2013 found that those under 50 experienced more non-specific symptoms before referral to specialists. Younger patients also had longer intervals between diagnosis and referral, highlighting a need for primary care awareness.
Scientists have developed a personalized platform called TARDIS that accurately detects circulating tumor DNA and signs of residual disease in breast cancer patients. The assay demonstrated a significant improvement in sensitivity, enabling earlier detection of tumors and monitoring patient response to chemotherapy.
A new 'liquid biopsy' blood test called TARDIS detects circulating tumor DNA in patient blood, enabling precise monitoring of disease progression and response to treatment. The test's high sensitivity could help plan surgical resection and radiation therapy after pre-operative therapy.
A liquid biopsy assay demonstrated high accuracy in detecting microsatellite instability (MSI) status in cancer patients, with an overall accuracy of 98.4%. The study showed that the assay could identify MSI-high tumors and predict clinical outcomes, offering potential benefits for personalized treatment planning.
A study published in Nature Immunology reveals that immune cells' activation state prior to anti-PD-1 therapy is crucial for cancer response. The researchers found a way to overcome resistance by activating T cells through vaccines, suggesting a new approach to enhance PD-1 inhibitors.
The GW Cancer Center is conducting a randomized, placebo-controlled phase III trial to investigate cemiplimab's safety and effectiveness in preventing recurrence and metastasis in high-risk cutaneous squamous cell carcinoma. The study aims to enroll over 400 participants worldwide.
A new study has found that elderly cancer patients who are HIV-positive have poorer outcomes compared to those without the virus. The research found higher mortality rates from breast and prostate cancers among HIV-infected patients.
Researchers compared outcomes in patients with and without HIV who received stage-appropriate cancer treatment after a cancer diagnosis at age 65. The study found no significant difference in overall survival between the two groups, suggesting that age alone may not be a determining factor in cancer treatment outcomes.
A new study has found that psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer. Patients who experienced stress-related disorders or stressful life events were 33% more likely to die from the disease compared to those who did not report stress.
The National Cancer Institute has recognized Sylvester Comprehensive Cancer Center as a top-tier US cancer center due to its outstanding research and clinical care. The designation is a testament to the dedication of every member of the cancer center.
A breakthrough new drug CBL0137 has proven effective in mice treated with chemotherapy and is being tested as a potential treatment for all types of cancer, including solid tumours. The drug works by reactivating the body's P53 pathway to kill off damaged cells.
Researchers discovered that natural killer (NK) cells can express PD-L1 and provide anti-tumor activity when treated with checkpoint inhibitors. PD-L1+ NK cells can control tumor growth by killing tumors and secreting cytokines, providing a new immunotherapeutic avenue.
Antonio Giordano, a Hollings Cancer Center clinical scholar, is researching novel treatments for triple-negative breast cancer. He aims to develop a PLK1-inhibitor drug and explore the role of tumor-infiltrating lymphocytes in prognosis.
Research from St. Jude Children's Research Hospital found a link between inherited BRCA2 mutations and an increased risk of childhood non-Hodgkin lymphoma. The study analyzed data from 1,380 lymphoma survivors and found that members with BRCA2 mutations were more likely to develop the disease.
A study published in JAMA Oncology reports higher than expected five-year survival rates for patients with melanoma, renal cell carcinoma, and non-small-cell lung cancer treated with nivolumab. The treatment showed durable responses and improved outcomes for patients without cancer-related symptoms.
A new AI tool developed by Dana-Farber Cancer Institute can extract high-value cancer outcomes from unstructured radiology reports with comparable accuracy to human reviewers. The tool, trained on over 14,000 imaging reports, was able to replicate human assessments of disease-free survival and progression-free survival.
A new, non-invasive bladder cancer treatment method uses a 'liquid biopsy' from urine to identify molecular underpinnings of each patient's unique bladder cancer. The technique, called conditional reprogramming or CR, has shown promising results in detecting and treating the disease.
The FDA has approved erdafitinib as a targeted therapy for patients with advanced bladder cancer who have specific gene mutations in the FGFR3 gene. The drug achieved a 40% overall response rate and was well-tolerated, offering an alternative to existing treatments.
Researchers at the University of Maryland and National Cancer Institute identified 12 distinct gene-pair relationships in tumor cells that could be targeted for cancer therapy. These relationships were associated with varying levels of expression in the two genes and correlated with cancer patient survival.
A global report found that one in three cancer patients struggle to access psychological support, with 34% saying it was not available despite needing it. The survey also identified key areas for improvement, including swift diagnosis, information-sharing, and integrated multidisciplinary care.
Tiny devices based on microfluidics can analyze bodily fluids to detect early signs of cancer, enabling widespread screening. They also help develop personalized treatments by predicting patient responses to drug candidates.
ASHG honors Drs. Weitzel and Blazer for their exceptional contributions to cancer genomics education, impacting thousands of patients globally. Their initiatives have prepared clinicians for leadership roles in translational research and improved healthcare outcomes.
A team at Fred Hutchinson Cancer Research Center has identified a gene called DUX4 that can prevent the immune system from recognizing and attacking cancer cells. This discovery suggests that blocking the activity of this gene might increase the success of immunotherapy treatments for a wide range of cancers.
Researchers discovered that leukemia stem cells suppress NKG2D-L proteins, evading the immune system. By inhibiting PARP1, these cells can be recognized and eliminated by NK cells.
Radiotherapy patients experiencing hurricane disasters had significantly worse overall survival rates than those completing treatment in normal circumstances. Longer disaster declarations were associated with increasingly worse survival outcomes.
Researchers discovered a cellular pathway linked to cancer that may benefit patients with hepatocellular carcinoma by reducing side effects and extending immunotherapy duration. The study found that blocking the IL-6/JAK1 pathway could resolve immunotherapy side effects and improve treatment outcomes.
Researchers have developed an AI algorithm that can analyze breast ultrasound images to detect cancer with high accuracy. The algorithm uses synthetic data to train itself, achieving nearly 100% classification rate on real-world images.
Researchers have identified an enzyme called LPCAT1 that plays a key role in tumor growth by changing the phospholipid composition of cancer cells' plasma membranes. When genetically depleted in mice, malignancies shrank dramatically, suggesting LPCAT1 as a potential new drug target for various cancer types.
The University of Colorado Cancer Center is enrolling patients in a Phase II clinical trial evaluating the effectiveness of Rucaparib, a PARP inhibitor, as maintenance therapy for endometrial cancer. The trial aims to determine the drug's ability to prevent cancer cell growth and death in patients with metastatic or recurrent disease.
Researchers have identified a new cell growth pathway that could lead to better treatments for metastatic cancers. The study found that the mEAK-7 gene is highly expressed in metastatic non-small cell lung cancer cells and plays a key role in cancer metastasis.
Researchers are testing a therapy called bermekimab, which blocks inflammation and pain-causing molecules in the immune system. The trial aims to improve outcomes in lung, pancreatic and ovarian cancer patients, with the goal of reducing symptoms such as weight loss and decreased mobility.
A worldwide coalition of researchers has agreed that light therapy is an effective intervention for preventing oral mucositis in head and neck cancer patients. The new guidelines recommend photobiomodulation therapy, a low-dose light therapy, to prevent the painful ulcers resulting from radiation therapy.
City of Hope scientists develop blood test to forecast breast cancer recurrence risk in patients with solid tumors. The innovative approach aims to personalize treatment strategies and improve patient outcomes.
A new probe has been developed to help surgeons detect cancer cells during surgery, with the potential to improve surgical outcomes for patients. The probe uses fluorescence imaging and has been published in Chemical Science, a study led by RCSI researchers.
A phase III trial found that a three-drug combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer. The treatment resulted in a median overall survival of 9 months compared to 5.4 months for standard therapy.
Researchers at Stanford University School of Medicine have developed a computer algorithm that integrates various predictive data to generate a single, dynamic risk assessment for cancer patients. The algorithm, termed CIRI, outperformed standard methods in predicting patient outcomes and identifying better treatment options.
A study found that a naturally occurring strain of the common cold, coxsackievirus CVA21, can target and destroy bladder cancer cells without causing harm to healthy cells. The treatment showed significant reduction in tumour burden and removal of disease in one patient after just one week.
A new IOF review emphasizes the importance of long-term follow-up to maintain bone health in childhood cancer survivors. The study highlights the need for careful monitoring and management to prevent premature onset of low bone mineral density and improve fracture risk.
A new study shows that niraparib can extend life for women with ovarian cancer who have undergone multiple rounds of chemotherapy. The study found that 27% of patients responded well to the drug and averaged 9.2 months until disease progression, offering hope for a meaningful treatment option.
A new study found that gastric cancer is affecting more young Hispanic people in the US, with poorer outcomes than older patients. Women under 40 were more likely to have diffuse-type tumours and stage IV disease at diagnosis, leading to a median overall survival of just 7 months.
A study by the National Cancer Institute found a clear dose-response relationship between radioactive iodine treatment and long-term risk of death from solid cancers, including breast cancer. The study estimated that for every 1,000 patients treated with standard doses, about 20-30 additional solid cancer deaths would occur.
The foundation awarded Continuation Grants to five Damon Runyon Clinical Investigators, providing an additional two years of funding totaling $400,000. The recipients are conducting patient-oriented cancer research with the goal of finding cures for cancer diagnosis, prevention and treatment.
A 65-year follow-up study of nearly 7,000 Norwegian patients with multiple sclerosis found an overall risk of developing cancer 14% higher than the general population. Respiratory cancer risk was particularly high at 66%, while urinary and central nervous system cancer risks were also significantly increased.
A Danish study of 32,000 haematological cancer patients found that one in five suffer from blood clots or bleeding, with varying risk levels depending on the type of cancer. The research highlights the need for individualized treatment and awareness of high-risk patients to prevent complications.
A new risk prediction model using clinical and radiological features can stratify individuals with lung nodules as having high or low risk of developing lung cancer. The model, which combines variables such as age, smoking history, and nodule characteristics, showed a sensitivity and specificity of 73% and 81%, respectively.
A Penn study shows a Moonshot-funded program can increase cancer patients' engagement in tobacco cessation treatments from 0% to 36%. The program's success is attributed to institutional buy-in and continuous dialogue with clinicians, which informed the development of additional support services.
Researchers sequenced canine cancer cell lines to identify human-like genetic changes driving canine cancers. The study found 61 genetic variants that match known drivers of human cancer, and showed sensitivity to human medicines.
A new systematic review highlights gaps in understanding cancer among LGBTI adolescents and young adults, who face barriers to health services. Researchers propose a Call to Action to reduce these disparities and improve cancer care for this at-risk population.
A national survey finds that half of the population believes cancer requires better treatments, and two-thirds expect most cancers to be curable by 2050. The UK public also supports a tax-funded NHS and wants closer partnerships between the public and private sectors to develop more effective cancer treatments.
A systematic review found that most non-cancerous adrenal tumors do not grow significantly over time, eliminating the need for repeated imaging. Patients with mild cortisol excess may still develop cardiovascular disease, but guidelines should be revised to reflect this low cancer risk and monitor metabolic health instead.
Research found statin therapy significantly reduced stroke risk and overall cardiovascular events in cancer patients who underwent radiation therapy for chest, head, or neck cancer. The study also showed a strong trend toward reduction in cardiovascular deaths.
Researchers at Huntsman Cancer Institute discovered a new experimental drug, selinexor, which may block a crucial survival pathway exploited by myelofibrosis cells. A clinical trial has been designed to examine the drug's effectiveness in patients with myelofibrosis.
Researchers identify barriers to trial accrual, including complexity in staying aware of available trials, identifying eligible patients, and enrolling them. The study suggests addressing these challenges through changes in trial-specific reimbursement and incentives for administrative costs.
A population-based cohort study from 4 Nordic countries found no link between TNFi use and increased cancer risk. However, a significant increase in malignant lymphomas was observed within the trial. Further analysis is needed to determine if this is due to psoriatic arthritis or TNFi treatment.
Researchers developed a biomarker test to predict disease-free survival and recurrence risk in patients with triple-negative breast cancer. The test uses formalin-fixed, paraffin-embedded tissues and has shown promise in predicting patient outcomes.
Researchers found that identifying a patient's Consensus Molecular Subtype (CMS) could help oncologists determine the most effective course of treatment. CMS categorizes colorectal cancer into four distinct subgroups based on tumor mutations, and each subgroup is associated with different treatment outcomes.
Researchers have developed a comprehensive database of synonymous mutations found in cancer, revealing their influence on cellular functions and disease processes. The SynMIC database contains information on 659,194 entries across 88 types of cancer, providing a valuable resource for cancer researchers.
Researchers found HPV16 antibodies develop in body between 6-40 years prior to throat cancer diagnosis, increasing risk significantly. The presence of these antibodies indicates a strong increased risk of disease, particularly among white people, with an estimated 100-fold increase compared to black people.
The seven-year ORATOR trial found no difference in survival between robotic surgery and radiation therapy, but patients receiving radiation experienced better swallowing outcomes. Participants in the surgery group were at risk for complications such as pain, bleeding, and hearing loss.
A nationwide survey of 487 women found that nearly two-thirds of breast cancer patients are unaware of surgical options that can minimize scarring. The study also revealed that many patients experience negative impacts from their scars, including feelings of self-consciousness and restricted clothing choices.